6533b862fe1ef96bd12c768a
RESEARCH PRODUCT
Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study
Massimo VicentiniManuel ZorziEmanuela BovoPamela MancusoMarco ZappaGianfranco ManneschiLucia MangonePaolo Giorgi RossiGrazia GrazziniPaola MantelliniAdele CaldarellaTeresa IntrieriEmanuela AnghinoniCarlo SenoreFrancesco TisanoAntonio Colanino ZiinoSabina MalignaggiGuido PassanisiMassimo RuggeAnna TurrinSilvano PifferMaria GentiliniRoberto RizzelloRiccardo PertileFlavio SensiRosaria CesaraccioTeresa InterieriStefano FerrettiNatalina CollinaChiara PetrucciAnna Clara FanettiLorella CecconamiMario FuscoMaria Francesca VitaleMarine CastaingAntonella IppolitoMassimo VarvaraPaola PesceRosa FilibertiElisabetta BorcianiPietro SeghiniFabrizio StracciMorena MalaspinaDiego SerrainoFabio FalciniOrietta GiulianiFabio PannozzoSimonetta CuratellaFrancesca CalabrettaPaola BellardiniGiuliano CarrozziLuigi BisantiAntonio Giampiero RussoAnna Rita SilvestriEnrica TidoneAdriano GiacominAlberto AzzoniWalter MazzuccoRosanna CusimanoCinzia CampariStefania CaroliMaria MichiaraPaolo SgargiAldo De TogniCaterina PalmonariClaudia CasellaAntonella Pupposubject
MaleCancer Researchmedicine.medical_specialtyColorectal cancerPrevalenceSocio-culturaleColonoscopyColorectal NeoplasmSettore MED/42 - Igiene Generale E Applicatacolorectal cancer screeningScreening programmeFeces03 medical and health sciences0302 clinical medicinecolonoscopyFaecal immunochemical test colonoscopy colorectal cancer screening epidemiology cancer registriesInternal medicineEpidemiologymedicineHumansStage (cooking)Early Detection of CancerAgedNeoplasm StagingProportional Hazards Modelscancer registriemedicine.diagnostic_testFaecal immunochemical testbusiness.industryIncidence (epidemiology)IncidenceMiddle Agedmedicine.diseaseImmunohistochemistryOncologyItalycancer registries030220 oncology & carcinogenesisRelative riskOccult BloodepidemiologyFeceFemaleNeoplasm GradingColorectal NeoplasmsbusinessHumandescription
To evaluate the impact of faecal immunochemical test (FIT) screening on stage distribution at diagnosis, and to estimate relative incidence rates by stage in screened at first and subsequent rounds vs. unscreened. We included all incident cases occurring in 2000-2008 in 50- to 71-year-olds residing in areas with an FIT-screening programme. Multinomial logistic models were computed to estimate the relative risk ratio (RRR) of stages I and IV, compared to stage II + III, adjusting for age, sex, geographical area, and incidence year. Proportions were then used to estimate incidence rate ratios (IRR) by stage for screened subjects at the first and at subsequent rounds vs. unscreened subjects, applying the expected changes in overall incidence during screening phases. 11,663 cancers were included: 5965 in not-invited and 5,698 in invited subjects, 3,425 of whom attendees. Compared to not-invited, invited subjects had RRR 2.04 (95% CI: 1.84; 2.46) of stage I and RRR 0.77 (95% CI: 0.69; 0.87) of stage IV. Differences were stronger comparing attendees vs. nonattendees. Interval cancers were more frequently stage I compared to non-invited (RRR 1.54; 95% CI: 1.15; 2.04), but there was no difference for stage IV. IRRs in screened at first round vs. unscreened were 4.6 (95% CI: 4.2; 5.1), 1.4 (95% CI: 1.3; 1.5) and 0.7 (95% CI: 0.6; 0.9) for stages I, II + III and IV, respectively; in the following rounds the IRRs of screened vs. unscreened were 1.4 (95% CI: 1.2; 1.6), 0.8 (95% CI: 0.7; 0.9) and 0.3 (95% CI: 0.1; 0.4) for stages I, II + III and IV, respectively. FIT screening reduces the incidence of metastatic cancers by about 70% after the first round.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-01-01 |